Biodegradable Nanoparticles for Targeted Antibiotic Delivery

用于靶向抗生素递送的可生物降解纳米颗粒

基本信息

  • 批准号:
    8293423
  • 负责人:
  • 金额:
    $ 37.14万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-07-10 至 2013-12-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Human infections by the intracellular bacterial pathogens Chlamydia trachomatis and C pneumoniae present an enormous health care problem. Infections by these pathogens have been associated with engendering and/or exacerbating several chronic diseases, and some of these Chlamydial infections have proved to be refractory to antibiotic therapy. The lack of therapeutic efficacy results from the attenuated metabolic rate of infecting chlamydiae under some circumstances, in combination with the modest intracellular concentrations achievable by normal delivery of such drugs to the inclusions within which chlamydiae reside in the host cell cytoplasm. The major therapeutic goal of the studies outlined here is to develop a means by which antibiotics or other therapeutic agents can be delivered in a targeted manner to the intracellular Chlamydial inclusion at effective concentrations, without toxicity to the host cell or infected tissue. Our initial studies indicate that Chlamydial infection elicits increased expression of host cell folic acid receptors (FAR), and that folic acid-conjugated nanoparticles may provide a novel and highly effective means of intracellular delivery of therapeutic agents to Chlamydia- infected cells. The working hypothesis underlying the studies proposed is that host cells infected with either C trachomatis or C pneumoniae can be cleared of actively- or persistently-infecting organisms via nanoparticle-mediated targeted delivery of effective concentrations of antibiotics known to work against active Chlamydial infections. We further hypothesize that nanoparticle-facilitated delivery will require reduced amounts of therapeutic materials, which could engender significant health care cost reductions. To pursue that end, three Specific Aims will be addressed. In Aim One, we will define the time-course of expression of folate receptors following C trachomatis infection of a relevant panel of human host cells in culture and in a mouse model of C trachomatis infection, and define the localization of folic acid receptors between the host cell and cytoplasmic inclusion membranes. In Aim Two, we will determine at what time point post-in vitro infection delivery of those nanoparticles is most effective, and whether delivery of antibiotics to infected cells by nanoparticles is effective in clearing C trachomatis infection. In addition, using fluorescence microscopy, we will study the intracellular trafficking of nanoparticles in infected and uninfected cells to understand the mechanism of nanoparticle targeting to inclusions. In Aim Three, using in vivo imaging, molecular genetics, and quantitative analytical methods, we determine if FAR targeted delivery of nanoparticle antibiotics to Chlamydia-infected mice clears synovial infection in vivo. If successful, results of this research will suggest a novel nanotechnology-based therapeutic regimen for effective treatment of an important health care problem. PUBLIC HEALTH RELEVANCE: Chlamydiae are associated with several chronic diseases, including inflammatory arthritis, tubal occlusion leading to ectopic pregnancy, and cervical cancer (C trachomatis); C pneumoniae has been compellingly associated with atherosclerosis, inflammatory arthritis, and temporal arteritis, among several others. The proposed research is expected to positively affect human health, because, it is expected to lead to the development of an effective approach for the treatment of persistent Chlamydial infections.
描述(由申请人提供):细胞内细菌病原体沙眼衣原体和肺炎衣原体引起的人类感染带来了巨大的医疗保健问题。这些病原体的感染与多种慢性疾病的发生和/或恶化有关,并且其中一些衣原体感染已被证明对抗生素治疗无效。缺乏治疗功效是由于在某些情况下感染衣原体的代谢率减弱,加上通过将此类药物正常递送至衣原体驻留在宿主细胞细胞质中的包涵体而可达到的适度的细胞内浓度。这里概述的研究的主要治疗目标是开发一种方法,通过该方法可以将抗生素或其他治疗剂以有效浓度有针对性地递送到细胞内衣原体包涵体,而不对宿主细胞或感染组织产生毒性。我们的初步研究表明,衣原体感染引起宿主细胞叶酸受体(FAR)的表达增加,并且叶酸缀合的纳米颗粒可能提供一种新颖且高效的方法,将治疗剂细胞内递送至衣原体感染的细胞。研究提出的工作假设是,感染沙眼衣原体或肺炎衣原体的宿主细胞可以通过纳米颗粒介导的靶向递送有效浓度的已知可对抗活动性衣原体感染的抗生素来清除活动性或持续性感染的生物体。我们进一步假设纳米颗粒促进的递送将需要减少数量的治疗材料,这可能会显着降低医疗保健成本。为了实现这一目标,将实现三个具体目标。在目标一中,我们将定义培养物中和沙眼衣原体感染小鼠模型中相关人类宿主细胞组在沙眼衣原体感染后叶酸受体表达的时间过程,并定义叶酸受体在沙眼衣原体感染之间的定位。宿主细胞和细胞质包涵膜。在目标二中,我们将确定在体外感染后的哪个时间点递送这些纳米颗粒最有效,以及通过纳米颗粒将抗生素递送至感染细胞是否能有效清除沙眼衣原体感染。此外,我们将使用荧光显微镜研究纳米颗粒在感染和未感染细胞中的细胞内运输,以了解纳米颗粒靶向包裹体的机制。在目标三中,我们利用体内成像、分子遗传学和定量分析方法,确定 FAR 向衣原体感染小鼠靶向递送纳米颗粒抗生素是否可以清除体内滑膜感染。如果成功,这项研究的结果将提出一种基于纳米技术的新型治疗方案,用于有效治疗重要的医疗保健问题。 公共卫生相关性:衣原体与多种慢性疾病有关,包括炎症性关节炎、导致宫外孕的输卵管阻塞和宫颈癌(沙眼衣原体);肺炎衣原体与动脉粥样硬化、炎性关节炎和颞动脉炎等密切相关。拟议的研究预计将对人类健康产生积极影响,因为预计它将导致开发出治疗持续性衣原体感染的有效方法。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Folic acid functionalized nanoparticles for enhanced oral drug delivery.
叶酸功能化纳米颗粒可增强口服药物输送。
  • DOI:
    10.1021/mp2005388
  • 发表时间:
    2012-07-02
  • 期刊:
  • 影响因子:
    4.9
  • 作者:
    Roger E;Kalscheuer S;Kirtane A;Guru BR;Grill AE;Whittum-Hudson J;Panyam J
  • 通讯作者:
    Panyam J
Targeted delivery of antibiotics to intracellular chlamydial infections using PLGA nanoparticles.
使用 PLGA 纳米颗粒将抗生素靶向递送至细胞内衣原体感染。
  • DOI:
    10.1016/j.biomaterials.2011.05.038
  • 发表时间:
    2011-09
  • 期刊:
  • 影响因子:
    14
  • 作者:
    Toti, Udaya S.;Guru, Bharath R.;Hali, Mirabela;McPharlin, Christopher M.;Wykes, Susan M.;Panyam, Jayanth;Whittum-Hudson, Judith A.
  • 通讯作者:
    Whittum-Hudson, Judith A.
Dendrimer-conjugated peptide vaccine enhances clearance of Chlamydia trachomatis genital infection.
树枝状大分子缀合肽疫苗可增强沙眼衣原体生殖器感染的清除。
  • DOI:
    10.1016/j.ijpharm.2017.05.045
  • 发表时间:
    2017-07-15
  • 期刊:
  • 影响因子:
    5.8
  • 作者:
    Ganda IS;Zhong Q;Hali M;Albuquerque RLC;Padilha FF;da Rocha SRP;Whittum-Hudson JA
  • 通讯作者:
    Whittum-Hudson JA
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jayanth Panyam其他文献

Jayanth Panyam的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jayanth Panyam', 18)}}的其他基金

TLR7/8 agonist design and delivery for effective anticancer immune response
TLR7/8 激动剂设计和递送以实现有效的抗癌免疫反应
  • 批准号:
    10643962
  • 财政年份:
    2021
  • 资助金额:
    $ 37.14万
  • 项目类别:
TLR7/8 agonist design and delivery for effective anticancer immune response
TLR7/8 激动剂设计和递送以实现有效的抗癌免疫反应
  • 批准号:
    10947664
  • 财政年份:
    2021
  • 资助金额:
    $ 37.14万
  • 项目类别:
TLR7/8 agonist design and delivery for effective anticancer immune response
TLR7/8 激动剂设计和递送以实现有效的抗癌免疫反应
  • 批准号:
    10424571
  • 财政年份:
    2021
  • 资助金额:
    $ 37.14万
  • 项目类别:
TLR7/8 agonist design and delivery for effective anticancer immune response
TLR7/8 激动剂设计和递送以实现有效的抗癌免疫反应
  • 批准号:
    10312341
  • 财政年份:
    2021
  • 资助金额:
    $ 37.14万
  • 项目类别:
Biodegradable Nanoparticles for Targeted Antibiotic Delivery
用于靶向抗生素递送的可生物降解纳米颗粒
  • 批准号:
    8130413
  • 财政年份:
    2010
  • 资助金额:
    $ 37.14万
  • 项目类别:
Sustained Release Curcumin Microspheres for Breast Cancer Chemoprevention
缓释姜黄素微球用于乳腺癌化学预防
  • 批准号:
    7751485
  • 财政年份:
    2009
  • 资助金额:
    $ 37.14万
  • 项目类别:
Sustained Release Curcumin Microspheres for Breast Cancer Chemoprevention
缓释姜黄素微球用于乳腺癌化学预防
  • 批准号:
    7894676
  • 财政年份:
    2009
  • 资助金额:
    $ 37.14万
  • 项目类别:
Biodegradable Nanoparticles for Targeted Antibiotic Delivery
用于靶向抗生素递送的可生物降解纳米颗粒
  • 批准号:
    7890520
  • 财政年份:
    2009
  • 资助金额:
    $ 37.14万
  • 项目类别:
Biodegradable Nanoparticles for Targeted Antibiotic Delivery
用于靶向抗生素递送的可生物降解纳米颗粒
  • 批准号:
    8080987
  • 财政年份:
    2009
  • 资助金额:
    $ 37.14万
  • 项目类别:
Biodegradable Nanoparticles for Targeted Antibiotic Delivery
用于靶向抗生素递送的可生物降解纳米颗粒
  • 批准号:
    7728645
  • 财政年份:
    2009
  • 资助金额:
    $ 37.14万
  • 项目类别:

相似国自然基金

本体驱动的地址数据空间语义建模与地址匹配方法
  • 批准号:
    41901325
  • 批准年份:
    2019
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
时空序列驱动的神经形态视觉目标识别算法研究
  • 批准号:
    61906126
  • 批准年份:
    2019
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
针对内存攻击对象的内存安全防御技术研究
  • 批准号:
    61802432
  • 批准年份:
    2018
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
  • 批准号:
    61802133
  • 批准年份:
    2018
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
  • 批准号:
    61872252
  • 批准年份:
    2018
  • 资助金额:
    64.0 万元
  • 项目类别:
    面上项目

相似海外基金

Climate Change Effects on Pregnancy via a Traditional Food
气候变化通过传统食物对怀孕的影响
  • 批准号:
    10822202
  • 财政年份:
    2024
  • 资助金额:
    $ 37.14万
  • 项目类别:
Investigating the Effect of FLASH-Radiotherapy on Tumor and Normal Tissue
研究 FLASH 放射治疗对肿瘤和正常组织的影响
  • 批准号:
    10650476
  • 财政年份:
    2023
  • 资助金额:
    $ 37.14万
  • 项目类别:
Clonal hematopoiesis and inherited genetic variation in sickle cell disease
镰状细胞病的克隆造血和遗传变异
  • 批准号:
    10638404
  • 财政年份:
    2023
  • 资助金额:
    $ 37.14万
  • 项目类别:
Functional, structural, and computational consequences of NMDA receptor ablation at medial prefrontal cortex synapses
内侧前额皮质突触 NMDA 受体消融的功能、结构和计算后果
  • 批准号:
    10677047
  • 财政年份:
    2023
  • 资助金额:
    $ 37.14万
  • 项目类别:
Functional, structural, and computational consequences of NMDA receptor ablation at medial prefrontal cortex synapses
内侧前额皮质突触 NMDA 受体消融的功能、结构和计算后果
  • 批准号:
    10677047
  • 财政年份:
    2023
  • 资助金额:
    $ 37.14万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了